187 related articles for article (PubMed ID: 36053168)
1. A call to action to harmonize patient-reported outcomes evidence requirements across key European HTA bodies in oncology.
Chassany O; Engen AV; Lai L; Borhade K; Ravi M; Harnett J; Chen CI; Quek RG
Future Oncol; 2022 Sep; 18(29):3323-3334. PubMed ID: 36053168
[TBL] [Abstract][Full Text] [Related]
2. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
3. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
4. Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies.
Harricharan S; Curran E; Lin HM; Walton L; Gurjar K; Nguyen K; Forsythe A
Future Oncol; 2023 Mar; 19(8):603-616. PubMed ID: 37083358
[TBL] [Abstract][Full Text] [Related]
5. Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?
Schaefer R; Hernandez D; Selberg L; Schlander M
J Comp Eff Res; 2021 Nov; 10(16):1187-1195. PubMed ID: 34583534
[No Abstract] [Full Text] [Related]
6. Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs-Can Alignment Be Enhanced?
Wolters S; Jansman FGA; Postma MJ
Value Health; 2022 Dec; 25(12):1958-1966. PubMed ID: 35752535
[TBL] [Abstract][Full Text] [Related]
7. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
8. Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies - can alignment be improved?
Wolters S; de Jong LA; Jansen C; Jansman FG; Postma MJ
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):251-265. PubMed ID: 37747280
[TBL] [Abstract][Full Text] [Related]
9. Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments.
Appiah K; Rizzo M; Sarri G; Hernandez L
J Comp Eff Res; 2024 Feb; 13(2):e230140. PubMed ID: 38174576
[No Abstract] [Full Text] [Related]
10. Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?
Chassagnol F; Marcelli G; Wagle J; Giuliani G; Traub D; Schaub V; Ruof J
Health Policy; 2020 Sep; 124(9):943-951. PubMed ID: 32622542
[TBL] [Abstract][Full Text] [Related]
11. Opportunities to improve the adoption of health-related quality of life evidence as part of the French Health Technology Assessment process.
Larose H; Lee M; Grueger J; Anota A; Naïditch N; Falissard B; Di Palma M; Chassany O; Khalfallah-Neelz L; Palazuelos-Muñoz S; Tetafort A
Health Res Policy Syst; 2023 Dec; 21(1):137. PubMed ID: 38115078
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of Seven Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies.
Jaksa A; Louder A; Maksymiuk C; Vondeling GT; Martin L; Gatto N; Richards E; Yver A; Rosenlund M
Value Health; 2022 Dec; 25(12):1967-1976. PubMed ID: 35760714
[TBL] [Abstract][Full Text] [Related]
13. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group.
Garfield S; Polisena J; S Spinner D; Postulka A; Y Lu C; Tiwana SK; Faulkner E; Poulios N; Zah V; Longacre M
Value Health; 2016; 19(5):577-87. PubMed ID: 27565275
[TBL] [Abstract][Full Text] [Related]
14. Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions.
Sola-Morales O; Curtis LH; Heidt J; Walsh L; Casso D; Oliveria S; Saunders-Hastings P; Song Y; Mercado T; Zusterzeel R; Mastey V; Harnett J; Quek RGW
Clin Pharmacol Ther; 2023 Aug; 114(2):325-355. PubMed ID: 37079433
[TBL] [Abstract][Full Text] [Related]
15. Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines.
Kalf RRJ; Vreman RA; Delnoij DMJ; Bouvy ML; Goettsch WG
Pharmacol Res Perspect; 2021 Apr; 9(2):e00742. PubMed ID: 33749172
[TBL] [Abstract][Full Text] [Related]
16. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.
Rand LZ; Kesselheim AS
J Law Med Ethics; 2020 Sep; 48(3):583-594. PubMed ID: 33021189
[TBL] [Abstract][Full Text] [Related]
17. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
Makady A; van Veelen A; Jonsson P; Moseley O; D'Andon A; de Boer A; Hillege H; Klungel O; Goettsch W
Pharmacoeconomics; 2018 Mar; 36(3):359-368. PubMed ID: 29214389
[TBL] [Abstract][Full Text] [Related]
18. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative Assessment.
Jarosławski S; Hanna E; Dabbous M; Chachoua L; Toumi M
Recent Results Cancer Res; 2019; 213():39-55. PubMed ID: 30543006
[TBL] [Abstract][Full Text] [Related]
20. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
